Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
186 hedge funds and large institutions have $2.16B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2020 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 69 increasing their positions, 66 reducing their positions, and 47 closing their positions.
17% more call options, than puts
Call options by funds: $38.6M | Put options by funds: $33M
5% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 66
10% less funds holding
Funds holding: 207 → 186 (-21)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
40% less capital invested
Capital invested by funds: $3.62B → $2.16B (-$1.46B)
43% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$63.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$31M |
| 3 |
DM
Deerfield Management
New York
|
+$23.3M |
| 4 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$19.1M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TimesSquare Capital Management
New York
|
-$55.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$46.8M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$31.2M |
| 4 |
BlackRock
New York
|
-$28.8M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$24.8M |
RETA Hedge Fund Activity: Q3 2020 in Review
186 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q3 2020, worth a combined $2.16B — down 40% from $3.62B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of RETA and 27 opened new positions — a net loss of 20 holders — while 66 trimmed existing stakes and 69 added.
The largest buyer was Invesco, adding an estimated $63.7M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $55.5M sold.
- 186 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q3 2020, down from 207 in Q2 2020.
- Funds reported $2.16B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q3 2020, down 40% quarter-over-quarter.
- 27 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q3 2020 and 47 closed out, a net change of -20 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q3 2020 was Invesco, an estimated $63.7M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q3 2020 was TimesSquare Capital Management, an estimated $55.5M sold.
Based on aggregated 13F filings for Q3 2020.